Literature DB >> 8383972

Inclusion body myositis and renal cell carcinoma. Report of two cases and review of the literature.

S R Ytterberg1, R I Roelofs, M L Mahowald.   

Abstract

OBJECTIVE: To describe the clinical course of 2 patients with concurrent inclusion body myositis and renal cell carcinoma and review published reports of inclusion body myositis associated with malignancy.
METHODS: Prospective followup of 2 patients. Review of published case reports and series of patients with inclusion body myositis.
RESULTS: Our 2 patients with inclusion body myositis and renal cell carcinoma had no improvement of strength following nephrectomy. Seven previously reported cases of inclusion body myositis and malignancy were identified and are discussed.
CONCLUSION: Findings in our 2 patients suggest that there is no etiopathologic relationship between inclusion body myositis and malignancy.

Entities:  

Mesh:

Year:  1993        PMID: 8383972     DOI: 10.1002/art.1780360319

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

Review 1.  Paraneoplastic rheumatic syndromes.

Authors:  H J Mitnick
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.686

2.  Inclusion Body Myositis: A Case Presenting with Respiratory Failure and Autopsy Findings Leading to the Hypothesis of a Paraneoplastic Cause.

Authors:  Christopher Dardis; Ariel Antezana; Kurenai Tanji; Paul J Maccabee
Journal:  Am J Case Rep       Date:  2017-06-23

3.  Identification of Hub Genes and Biological Pathways in Inclusion Body Myositis Using Bioinformatics Analysis.

Authors:  Yue Wu; Zijun Zhao; Jinru Zhang; Yaye Wang; Xueqin Song
Journal:  Int J Gen Med       Date:  2022-02-09

4.  Paraneoplastic Polymyositis Due to Renal Cell Carcinoma in a Patient with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Shoko Noda-Narita; Mami Kanzaki; Yoshikazu Uesaka; Tatsuya Suwabe; Keiichi Kinowaki; Yuhji Marui; Junichi Hoshino; Naoki Sawa; Yoshifumi Ubara
Journal:  Intern Med       Date:  2021-05-29       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.